PFBT
KALV

Parkside Financial Bank & Trust’s KalVista Pharmaceuticals KALV Stock Holding History

Parkside Financial Bank & Trust’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$805 Hold
40
– – ﹤0.01% 2426
2025
Q4 		$646 Hold
40
– – ﹤0.01% 2500
2025
Q3 		$488 Hold
40
– – ﹤0.01% 2578
2025
Q2 		$453 Buy
+40
New +$489 ﹤0.01% 2598

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parkside Financial Bank & Trust's KALV Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 40 shares worth $805. The position accounts for ﹤0.01% of the portfolio, ranked #2426.

Parkside Financial Bank & Trust first reported a position in KALV in Q2 2025 and has held it in 4 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Parkside Financial Bank & Trust held 40 shares of KalVista Pharmaceuticals worth $805 as of Q1 2026.
  • Parkside Financial Bank & Trust left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2426 holding.
  • Parkside Financial Bank & Trust first reported a position in KalVista Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.